Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
4.

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Giaccone G, Rodriguez JA.

Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. Review.

PMID:
16270096
6.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S.

Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62. Review.

PMID:
19483740
7.

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.

Wong KK.

Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. doi: 10.1016/S0169-5002(08)70100-4. Review.

PMID:
18513579
8.

Impact of EGFR mutation analysis in non-small cell lung cancer.

Yamamoto H, Toyooka S, Mitsudomi T.

Lung Cancer. 2009 Mar;63(3):315-21. doi: 10.1016/j.lungcan.2008.06.021. Review.

PMID:
18760859
9.

EGFR mutations and the terminal respiratory unit.

Yatabe Y.

Cancer Metastasis Rev. 2010 Mar;29(1):23-36. doi: 10.1007/s10555-010-9205-8. Review.

PMID:
20135199
10.

EGFR FISH versus mutation: different tests, different end-points.

Cappuzzo F.

Lung Cancer. 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. Review.

PMID:
18367287
11.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W.

Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Review.

13.

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.

Bonomi PD, Buckingham L, Coon J.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. Review.

14.

Genomic approaches to lung cancer.

Thomas RK, Weir B, Meyerson M.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s. Review.

15.

[A simple view on lung cancer biology: The EGFR pathway].

Ruppert AM, Wislez M, Poulot V, Lacave R, Antoine M, Cadranel J.

Rev Mal Respir. 2011 Apr;28(4):565-77. doi: 10.1016/j.rmr.2011.03.005. Review. French.

PMID:
21549910
16.

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.

Barton S, Starling N, Swanton C.

Curr Cancer Drug Targets. 2010 Dec;10(8):799-812. Review.

PMID:
20718710
17.

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.

Suda K, Tomizawa K, Mitsudomi T.

Cancer Metastasis Rev. 2010 Mar;29(1):49-60. doi: 10.1007/s10555-010-9209-4. Review.

PMID:
20108024
18.

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

Fukui T, Mitsudomi T.

Gen Thorac Cardiovasc Surg. 2008 Mar;56(3):97-103. doi: 10.1007/s11748-007-0193-8. Review.

PMID:
18340507
19.

[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].

Schwab R, Peták I, Pintér F, Szabó E, Kánya M, Tamási A, Várkondi E, Almási A, Szokolóczi O, Pápay J, Moldvay J, Kéri G, Kopper L.

Orv Hetil. 2005 Nov 13;146(46):2335-42. Review. Hungarian.

PMID:
16370245
20.

[Translational research on lung cancer--EGFR gene mutation].

Kosaka T, Endoh H, Yatabe Y, Mitsudomi T.

Gan To Kagaku Ryoho. 2005 Jun;32(6):750-8. Review. Japanese.

PMID:
15984511
Items per page

Supplemental Content

Support Center